Celgene Corp. (CELG)

95.71
NASDAQ : Health Technology
Prev Close 95.68
Day Low/High 95.16 / 96.00
52 Wk Low/High 58.59 / 98.97
Avg Volume 4.01M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 67.81B
EPS 5.70
P/E Ratio 13.11
Div & Yield N.A. (N.A)

Today's Good, Bad and Ugly

"Two hundred thousand dollars is a lot of money. We're gonna have to earn it." --Blondie, "The Good, The Bad and The Ugly" Let's look at the good, the bad and the ugly (my new daily feature) so far in today's trading session: The Good Biotech is dan...

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Celgene Has a $125 Price Target

Celgene Has a $125 Price Target

We can see the impressive reversal in the share price

Celgene Beats Estimates, Raises Earnings Outlook

Celgene Beats Estimates, Raises Earnings Outlook

Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.

Trade of the Week: Long SPY Puts

Let's make August $217 monthly puts of the SPDR S&P 500 ETF our Trade of the Week. These puts closed at $2.50 yesterday, and this is a bearish bet. There are several reasons why I feel stocks could decline over the near term, including: Continuing O...

Morning Movers: BUD, VZ, CELG, GS

Morning Movers: BUD, VZ, CELG, GS

Anheuser-Busch increases its offer for SABMiller after Brexit while the Federal Reserve prepares for action against Goldman Sachs.

Beware of False Profits

"Beware of false prophets, who come to you in sheep's clothing but inwardly are ravenous wolves." -- Matthew 7:15 I try to exclude personal experiences from my diary and only include observations related to the markets. But I have to start the morni...

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Chipotle, Wendy's on the bull side and gold stocks on the bear side.

I'm Bullish on Biotechs

The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...

Biotechs and Builders Will Rock 2Q Earnings

Biotechs and Builders Will Rock 2Q Earnings

A look at who will be up and who will down this earnings season.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Celgene Shares Likely to Jump on Potential $2B 'Orphan' Drug: RBC

Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.

5 Stocks I Like for 2016's Second Half

5 Stocks I Like for 2016's Second Half

From Celgene to Ford, these names look promising.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.

My Takeaways and Observations

My month was made by Double D's comments, and I mean it.  At my core I am a softie, and D's sweet words tugged at my heart. I shared them with my family. Bottom line to me on the markets: This week's events reset global economic and profits growth l...

Worst Is Yet to Come for Celgene?

The stock could be bottoming ... or headed lower.

3 Finds in Biotech's 'Pocket of Value'

3 Finds in Biotech's 'Pocket of Value'

Large biotech stocks are still at their cheapest valuations since 2011.

One Direction, Separate Leadership Positions Prove Vital to Celgene’s Success

One Direction, Separate Leadership Positions Prove Vital to Celgene’s Success

While many companies combine the roles of the CEO and Chairman of the Board, Celgene has found success in keeping those duties separate.

Looking for Relief From Biotech Pain

A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.

Cramer: Here's What's Really Behind This Hatred for Biotechs

This is the group that is the most dangerous politically.

Takeaways and Observations

My thanks to James Gentile for substituting for me yesterday. Here are my takeaways and observations from yesterday's session: It was Groundhog Day on Wall Street again. We finished down, but well off of the session lows. I did no trading. The U.S. ...

My Takeaways and Observations

Buyers live higher, sellers live lower. Markets are still Fed-centric and governed by the last lean by Yellen. Ali Ali Ali!  Here's a very good column from El Capitan.   Apple (AAPL) is Crapple (Part Deux)  Fastenal (FAST) is always a good proxy for...

My Latest Trades

Here's a rundown of the trades that I've made so far this morning: I sold my SPY June $208 puts at breakeven a few minutes ago. There are only two weeks left until this put expires, so I'm moving on. I've liquidated the balance of my four-stock biot...

My Morning Musings

Phil (played by Bill Murray): What would you do if you were stuck in one place and every day was exactly the same, and nothing that you did mattered? Ralph: That about sums it up for me. -- Groundhog Day Wednesday was a relatively uneventful trading...

My Takeaways and Observations

Venezuela is the new Greece.  Icahn goes for some Allergan (AGN) -- a name of mine -- but his impact is muted after missteps in the energy space and elsewhere.   Nobody likes short people,  but I grow shorter daily. (Note: We got little hands and li...

Celgene May Be Ready to Stage a Recovery

CELG needs to close above its April highs to kickstart a rally to around the $120 area.